SAC Capital hit with $4.6 billion "racketeering" suit

Fri Feb 24, 2006



Using the same racketeering statutes that are often applied in cases against the mafia and drug cartels, the pharmaceutical company Biovail on February 22 filed a suit in New Jersey court accusing Steve Cohen's $7 billion SAC Capital Advisors of engineering and executing an elaborate stock manipulation scheme in 2003 and 2004 that battered the drugmaker's stock in an effort to produce profits from short-selling.

Canada's largest drug company is requesting a jury trial and is seeking $4.6 billion in damages from SAC, which it claims led a "bear attack" to devalue Biovail's stock and make it a sitting duck for profitable shorting activity. Also implicated in the alleged conspiracy and named in the suit are brokers, independent analysts and other hedge funds.

Prior to 2002, SAC Capital Advisors generated an average annual return in the...

ISSN: 2151-1845 / CDC10004H

Register

By registering you will receive

  • A monthly newsletter on your specified areas of interest
  • A fortnightly update on the sector

Free Trial

Take a trial today and access

  • Performance news, fund launches, regulation changes and people moves
  • Profiles of fund managers, investors and distributors
  • Live league tables
  • Investor mandates


Popular Searches on HFI